Pharmaceutical Intervention for Pulmonary Embolism in a Rectal Cancer Patient Treated with New Assisted Chemotherapy

doi:10.19803/j.1672-8629.2021.01.16

Abstract

Abstract: Objective To introduce the pharmaceutical disposal one case of pulmonary embolism induced by bevacizumab.Methods Two clinical pharmacists participated in the evaluation of adverse reactions of pulmonary embolism induced by bevacizumab in combination with chemotherapy by consulting related literature and guidelines.Based on the patient's condition and willingness,the pharmacist gave advice on the selection of anticoagulants.Results The clinical pharmacists recommended solutions to the ADR,the physician adopted the recommendation,the patient's pulmonary embolish was well controlled.Conclusion Clinical pharmacists are expected to cooperate with clinicians,give a top priority to the safety of patients and give advice on clinical rational drug use.

Key words: clinical pharmacist, pulmonary embolism, adverse drug reaction

CLC Number:

R969.3

QU Guohong, CHEN Zhe. Pharmaceutical Intervention for Pulmonary Embolism in a Rectal Cancer Patient Treated with New Assisted Chemotherapy[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 80-83.

References

[1] Ferrara N,Hillan KJ,Gerber HP.Discovery and development of bevacizumab,an anti-VEGF antibody for treating cancer[J].Nat Rev Drug Discov,2004,3(5):391-400.
[2] Keating GM .Bevacizumab:a review of its use in advanced cancer[J].Drugs,2014,74(16):1891-1925.
[3] Escudier B,Pluzanska A,Koralewski P,et al.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised,double-blind phase III trial[J].Lancet,2007,370(9605):2103-2111.
[4] Yan CR,Zhang MY,Ma WB.Recent advance in bevacizumab for high-grade gliomas[J].Chinese Journal of Neurosurgery(中华神经外科杂志),2016,32(1):88-90.
[5] Xu BH,Jiang ZF,Shen ZZ,et al.Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer:findings from the ATHENA study[J].Chin Med J(Engl),2012,125(5):764-769.
[6] Burger RA,Brady MF,Bookman MA,et al.Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2011,365(26):2473-2483.
[7] Niho S,Kunitoh H,Nokihara H.Randomized phase II study of first-line carboplatin- paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer[J].Lung Cancer,2012,76:362-367.
[8] Khorana AA,Francis CW,Culakova E,et al .Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J].Journal of Thrombosis and Haemostasis,2007,5(3):632-634.
[9] Zhao R,Zhao BQ,Zhang YH.Adverse reactions of bevacizumab in the treatment of malignant tumor[J].Chinese Journal of New Drugs(中国新药杂志),2003,22(17):2097-2102.
[10] Pu J,Chan R,Ng G,et al.Using bevacizumab in the fight against malignant glioma:First results in Asian patients[J].Hong Kong Med J,2011,17(4):274-279.
[11] Nalluri SR,Chu D,Keresztes R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:meta-analysis[J].JAMA,2008,300(19):2277.
[12] Kilickap S,Abali H,Celik I.Bevacizumab,bleeding,thrombosis,and warfarin[J].Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2003,21(18):3542-3543.
[13] Zachary I.Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor[J].American Journal of Physiology-Cell Physiology,2001,280(6):1375-1386.
[14] Tam BYY,Wei K,Rudge JS,et al.VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis[J].Nature Medicine,2006,12(7):793-800.
[15] Hesser BA.Down syndrome critical region protein 1 (DSCR1),a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells[J].Blood,2004,104(1):149-158.
[16] Cui XL,Wan ZR,Hou KL,et al.Overview of Dugs Increasing the Risk of VTE or Thrombosis in Patients with Cancer[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2017,14(7):430-434.
[17] Chikako M,Yugo C,Satoko S,et al.Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database[J].Journal of oncology pharmacy practice,2016,24(1):22-27.
[18] Chinese Thoracic Society Pulmonary Embolism and Pulmonary Vascular Disease Group.practice guidelines in pulmonary throm-boembolism:Prevention,Screening,and Treatment[J].National Medical Journal of China(中华医学杂志),2018,98(14):1060-1087.
[19] Khorana AA,Noble S,Lee AYY,et al.Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism:guidance from the SSC of the ISTH[J].Journal of Thrombosis and Haemostasis,2018,16(9):1891-1894.
[20] The EINSTEIN-PE Investigators.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].New England Journal of Medicine,2012,366(14):1287-1297.
[21] Young AM,Marshall A,Thirlwall J,et al.Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism:results of a randomized trial (SELECT-D)[J].Journal of Clinical Oncology,2018,36(20):2017-2023.